A epidemia causada pelo vírus da imunodeficiência humana (HIV) é a mais importante das ultimas décadas. A despeito dos avanços no conhecimento da patogenia do vírus e da resposta imune à infecção, até o momento não existe uma vacina eficaz contra a aquisição do HIV. Diversas linhas de evidência indicam que anticorpos neutralizantes ou ligadores, linfócitos T CD4+ e T CD8+ desempenham um papel importante na imunidade contra o HIV. Os anticorpos que são capazes de neutralizar o HIV são direcionados principalmente à glicoproteína do envelope do vírus (env), mas os candidatos vacinais baseados na proteína de envelope gp120 monomérica testados até hoje falharam em induzir proteção nos ensaios de eficácia. Avanços no entendimento da estrutura e função da glicoproteína env tem facilitado o desenvolvimento de uma nova geração de imunógenos baseada em trímeros mais estáveis e solúveis da glicoproteína gp140. Em uma formulação vacinal além da escolha do antígeno, os adjuvantes desempenham um papel fundamental. Os adjuvantes são conhecidos por aumentar a imunogenicidade das vacinas, e nos últimos anos vários compostos, incluindo agonistas de receptores do tipo Toll (TLR) e NOD (NLR) têm demonstrado eficácia em ensaios clínicos. Em estudos prévios, nosso grupo demonstrou que a imunização de camundongos com uma vacina de DNA codificando 18 epítopos para linfócitos T CD4+ do HIV-1 (HIVBr18), foi capaz de induzir resposta específica e ampla de linfócitos T CD4+ e T CD8+. Devido ao importante papel do efeito auxiliar de linfócitos T CD4+ na resposta humoral nas imunizações assistidas por diversos adjuvantes, o objetivo central do trabalho foi verificar se a imunização inicial com a vacina de DNA HIVBr18 seria capaz de aumentar a magnitude/qualidade de resposta imune humoral e celular induzida pelo trímero de gp140 na presença de diferentes adjuvantes. Para tal, camundongos BALB/c foram imunizados inicialmente com a vacina HIVBr18 ou com o vetor vazio e posteriormente com a proteína gp140 na presença dos adjuvantes: completo de Freund (ACF), poly IC, CpG ODN 1826, Monofosforil lipídeo A (MPL), Muramildipeptídeo (MDP), Imiquimod (R837), e Resiquimod (R848). Observamos que a imunização inicial com HIVBr18 foi capaz de fornecer um auxílio cognato para a proliferação específica de linfócitos T CD4+ e T CD8+ e também para a produção da citocina IFNy. A análise da xx resposta humoral mostrou que a imunização inicial com a vacina HIVBr18, foi capaz de influenciar a produção das subclasses de imunoglobulinas, independente do adjuvante testado. No presente trabalho, também analisamos a influência dos adjuvantes na imunogenicidade da gp140. Os animais que receberam os adjuvantes MPL, poly IC e CpG ODN 1826 apresentaram títulos de anticorpos estatisticamente superiores quando comparados aos animais que receberam os adjuvantes Alum, MDP, R837 e R848. Observamos que os animais imunizados com a gp140 na presença dos diferentes adjuvantes desenvolveram células B do centro germinativo e células TCD4+ auxiliar foliculares. Estes resultados nos permitem concluir que a imunização inicial com HIVBr18 é capaz de alterar a qualidade da resposta humoral e celular gp140- específica. Assim, essa formulação poderia ser utilizada para auxiliar e/ou direcionar a resposta imune induzida por outros imunógenos como por exemplo o trímero de gp140. Podemos concluir também que diferentes formulações de adjuvantes que se encontram em ensaios clínicos como poly IC, CpG ODN e MPL podem ser capazes de induzir um resposta imune humoral e celular tão ou mais potente que aquela induzida pelo ACF / The epidemic caused by the human immunodeficiency virus (HIV) is the most important in the last decades. Despite advances in the knowledge about virus pathogenesis and immune response to infection, until now there is not an effective vaccine against HIV acquisition. Several evidences indicate that neutralizing or binding antibodies, CD4+ and CD8+ T lymphocytes play an important role in immunity against HIV. The antibodies that are able to neutralize HIV are primarily directed against the virus envelope glycoprotein (env), but the vaccine candidates based on monomeric gp120 envelope protein tested so far failed to induce protection in efficacy trials. Advances in understanding the structure and function of the env glycoprotein have facilitated the development of a new generation of immunogens based on trimers, a more stable and soluble form of gp140 glycoprotein. In a vaccine formulation, in addition to the antigen, adjuvants play a pivotal role. Adjuvants are known to increase the immunogenicity of vaccines and, in the last years, several compounds, including agonists of Toll-like receptors (TLR) and NOD (NLR), have presented efficacy in clinical trials. In previous work, our group demonstrated that immunization of mice with a DNA vaccine (HIVBr18) encoding 18 CD4+ T cells epitopes from HIV-1 was able to induce a broad CD4+ T and CD8+ T cells specific response.. Given the important role of CD4+ T cells in the humoral response after adjuvant-assisted immunization, the aim of the study was to verify whether an initial immunization with the DNA vaccine HIVBr18 could increase the magnitude/quality of humoral and cellular immune response induced by gp140 trimer in the presence of different adjuvants. Therefore, BALB/c mice were initially immunized with the vaccine HIVBr18 or empty vector and then with gp140 in the presence of the following adjuvants: Freund\'s complete (CFA), poly IC, CpG ODN 1826, monophosphoryl lipid A (MPL), Muramyl dipeptide (MDP), Imiquimod (R837), and Resiquimod (R848). We observed that initial immunization with HIVBr18 was able to provide cognate help for specific CD4+ and CD8+ T cells proliferation and also for IFN-y production. Analysis of humoral response showed that initial immunization with the HIVBr18 vaccine was able to alter the production of immunoglobulin subclasses independent of the adjuvant tested. This work also analyzed the influence of adjuvants on the immunogenicity of gp140. Mice that received the adjuvant MPL, poly IC and CpG ODN 1826 presented higher antibody titers when compared to animals that received Alum, MDP, R837 and R848. We observed that mice immunized with gp140 in the presence of all adjuvants tested developed germinal center B cells and follicular helper T cells (TFH). We conclude that initial immunization with HIVBr18 is able to alter the quality of specific humoral and cellular immune responses.. Therefore, this formulation could be used in combination with other immunogens, such as gp140, to help/redirect the immune response. We also conclude that the adjuvants that are in clinical trials such as poly IC, MPL and CpG ODN 1826 may be able to induce stronger humoral and cellular response than CFA

BACKGROUND:Tumor cell lines that can be tracked in vivo during tumorigenesis and metastasis provide vital tools for studying the specific cellular mechanisms that mediate these processes as well as investigating therapeutic targets to inhibit them. The goal of this study was to engineer imageable mouse mammary tumor cell lines with discrete propensities to metastasize to bone in vivo. Two novel luciferase expressing cell lines were developed and characterized for use in the study of breast cancer metastasis to bone in a syngeneic mouse model.RESULTS:The 4 T1.2 luc3 and 66c14 luc2 cell lines were shown to have high levels of bioluminescence intensity in vitro and in vivo after orthotopic injection into mouse mammary fat pads. The 4 T1.2 luc3 cell line was found to closely model the sites of metastases seen in human patients including lung, liver, and bone. Specifically, 4 T1.2 luc3 cells demonstrated a high incidence of metastasis to spine, with an ex-vivo BLI intensity three orders of magnitude above the commercially available 4 T1 luc2 cells. 66c14 luc2 cells also demonstrated metastasis to spine, which was lower than that of 4 T1.2 luc3 cells but higher than 4 T1 luc2 cells, in addition to previously unreported metastases in the liver. High osteolytic activity of the 4 T1.2 luc3 cells in vivo in the bone microenvironment was also detected.CONCLUSIONS:The engineered 4 T1.2 luc3 and 66c14 luc2 cell lines described in this study are valuable tools for studying the cellular events moderating the metastasis of breast tumor cells to bone.

Das Kolonkarzinom besitzt aufgrund seiner hohen Inzidenz und der zahlreichen Möglichkeiten, mittels moderner Therapiestrategien auf den Krankheitsverlauf Einfluss zu nehmen, eine hohe Relevanz für den klinischen Alltag. Etwa die Hälfte der an einem kolorektalen Karzinom erkrankten Patienten weisen Lebermetastasen auf, welche entweder bereits bei der primären Diagnosestellung vorliegen oder sich im weiteren Krankheitsverlauf ausbilden. Bei der Mehrzahl der Patienten mit Lebermetastasen ist derzeit nur eine palliative Therapie möglich. Die genaue Analyse kolorektaler Lebermetastasen ist somit unerlässlich, um eine gezielte Entwicklung neuer, effizienter Therapiestrategien für dieses große Patientenkollektiv zu ermöglichen. Ziel dieser Arbeit war es, möglichst genau Zytokinprofil, lymphozytäres Infiltrationsmuster und Verhältnis von pro- zu antiangiogenetischen Faktoren im Lebermetastasengewebe über einen biologisch maßgeblichen Wachstumszeitraum zu charakterisieren, um zu einem besseren Verständnis von Tumorimmunologie und Wachstumsverhalten kolorektaler Lebermetastasen beizutragen. Zu diesem Zweck wurde in einem Mausmodell die Ausbildung kolorektaler Lebermetastasen nach intraportaler Injektion von Tumorzellen (CT26.WT) untersucht. / Because of its high incidence and the numerous therapeutic strategies which allow the clinician to influence the course of the disease colorectal carcinoma figures prominently in the clinical daily routine. About half the patients with colorectal carcinoma suffer from hepatic metastasis, which is either already present at the primary diagnosis or develops later in the course of the disease. At present the majority of patients with hepatic metastasis can only be offered palliative therapy. A detailed analysis of hepatic metastasis is therefore essential for the specific development of new and efficient therapeutic strategies for this group of patients. The objective of this work was to characterize the cytokine profile, the lymphocytic infiltration patterns and the ratio of angiogenic and antangiogenic factors in the tissue of colorectal hepatic metastases as precisely as possible over a biologically significant timespan, thus contributing to a better understanding of tumor immunology and tumor growth. With this aim in view we analyzed the development of colorectal hepatic metastases in a mouse model after the intraportal injection of tumor cells (CT26.WT).

Vaccinia virus (VACV) is an enveloped DNA virus, member of the Orthopoxviridae genus. VACV genome size is about 200 kbp. This huge genome capacity allows VACV to encode a set of factors that are non-essential for virus replication and spread in vitro. While these factors are needed for interfering with host immune responses, VACV remains strongly immunogenic. Cell-mediated and humoral immune responses in atopic disorders are deregulated to a certain extent, leading to complications in case of infection or vaccination with vaccines based on replicating viruses, such as eczema vaccinatum caused by VACV. VACV effects on immune responses consist among others in the inhibition of expression of type I interferon (IFN) at various levels - for example in a specific inhibition of phosphorylation of the interferon regulatory factor-3 (IRF-3) via inhibition of the activity of TANK-binding kinase 1 (TBK 1) that normally phosphorylates IRF-3. Phosphorylation allows IRF-3 to translocate into the nucleus where it initiates transcription of IFNβ followed by induction of expression of IFN and interferon stimulated genes. Expression of these genes is shut down when IRF-3 activity is inhibited. To overcome this block, a recombinant VACV expressing murine IRF-3 under VACV p7.5 promotor (WR-IRF3) was generated....

The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file. Title from PDF of title page (University of Missouri--Columbia, viewed on January 5, 2010). Vita. Thesis advisor: Habib Zaghouani. Includes bibliographical references.

Epidemiological evidence linking dietary folate deficiency and risk for colorectal cancer is conflicting. Studies using animal models indicate that timing, dose and presence of pre-malignant lesions will influence whether folate deficiency prevents or promotes tumor formation. In this thesis a new model of spontaneous tumor formation due to long-term dietary folate deficiency alone, in non-transgenic mice and without carcinogen induction, is developed. The mechanisms by which folate deficiency might influence cancer risk are also examined. / BALB/c mice, with or without a null allele in a key folate-metabolizing enzyme, Methylenetetrahydrofolate reductase (Mthfr ), develop intestinal tumors due to dietary folate deficiency alone. On folate-deficient (FD) diets, 12.5% of Mthfr+/+ mice and 28.1% of Mthfr+/- mice developed tumors; mice on control diet (CD) did not. C57B1/6 mice (a strain resistant to other methods of tumor induction) placed on the same diets for the same amount of time did not develop any tumors. To investigate possible mechanisms the levels of DNA damage (dUTP/dTTP ratio and p-H2AX staining) and DNA methylation (thin layer chromatography) were examined. FD BALB/c, but not C57B1/6 mice, had a trend towards increased dUTP/dTTP and DNA double-strand breaks and decreased global DNA methylation compared to CD mice. To determine why the FD diet affects the BALB/c and not the C57Bl/6 strain, the expression of genes involved in folate metabolism was examined. Several changes in gene expression were observed. In particular, BALB/c mice had increased Mthfr expression and MTHFR activity compared to C57Bl/6 mice. Increased MTHFR activity may deplete 5,10-methylenetetrahydrofolate supplies for the dTMP synthesis, increasing the dUMP levels and, possibly, DNA damage. The levels of several DNA repair genes were also examined. Two genes involved in base excision repair, Thymine DNA glycosylase (Tdg) and Apurinic/apyrimidinic endonuclease 1 (Apex1), were increased in FD C57B1/6 compared to FD BALB/c mice suggesting increased DNA repair capacity. / These results support the evidence that dietary folate deficiency promotes intestinal tumor formation possibly through increased DNA damage, with subsequent defects in DNA repair.

Development of specific DNA methylation patterns is required for normal spermatogenesis. DNA methyltransferases (DNMTs) use S-adenosylmethionine (SAM) produced in a pathway requiring 5,10-methylenetetrahydrofolate reductase (MTHFR). This thesis describes: testicular phenotype differences derived from Mthfr-deficiency in different mouse strains; the cellular Mthfr expression pattern during male germ cell development; and finally, changes to the DNA methylation of Mthfr-deficient sperm. Mthfr-deficient BALB/c, but not C57BL/6, mice have reduced neonatal germ cell proliferation but both have abnormal germ cells as adults. Germ cell MTHFR expression differed developmentally in parallel with DNMTs associated with de novo methylation. Sperm from mice with reduced Mthfr levels or dietary folate deficiency had differential DNA methylation at multiple loci, compared to wildtype mice, indicating that maintenance as well as acquisition of methylation can be altered by SAM-reduction. These results highlight the important role of folate in sperm development throughout life.

Spinal cord injury (SCI) results in a well-orchestrated inflammatory response which causes secondary tissue damage. Activated macrophages contribute to this cytotoxic response, which includes damage to neurons, glia and myelin, and tissue loss that worsens functional outcomes after SCI. However, activated macrophages in the spinal cord under other conditions are not cytotoxic, such as after intraspinal injection of lysophosphatidylcholine (LPC), a potent demyelinating agent. Recovery from SCI may be optimized by reducing the detrimental effects of macrophages while promoting their beneficial ones. Therefore, I compared spinal cord tissue, as well as purified macrophages, from mice after SCI (cytotoxic response) and intraspinal LPC injection (non-cytotoxic response). As a first step to carry out this work, I characterized the injury parameters for SCI contusion injury (i.e. injury force and spinal cord displacement) in mice using the Infinite Horizons impactor (Chapter 2). This lesioning model was used in other work for the thesis. The role T cells may play in mediating macrophage activation after LPC microinjection and SCI was also assessed using Nude mice (Chapter 3). Next, Affymetrix GeneChip analysis was carried out on spinal cord tissue obtained at the peak of the macrophage response after SCI and intraspinal LPC injection to identify potential candidate genes that may control the divergent inflammatory responses (Chapter 4). Several potential genes were identified. I next characterized the expression and role of one of these genes, MAPK activated protein kinase 2 (MK2), and showed that it mediates secondary tissue damage after SCI via several mechanisms (Chapter 5). The differences in gene expression profiles of macrophages purified from the spinal cord after SCI and LPC-injection were also assessed (Chapter 6). This microarray analysis of macrophages led to the identification of 10 novel candidate genes, two of which were validated at the protein level. Finally, I also examined the expression and role of secretory leukocyte protease inhibitor (SLPI) in SCI (Chapter 7). Using a combination of knockout/overexpressing transgenic mice and recombinant SLPI, I found that SLPI mediates protective anti-inflammatory effects after SCI. In conclusion, work done for this thesis has led to the identification of several novel molecules that influence the inflammatory response after injury and thus have led to the identification of potentially novel targets for the development of pharmacological approaches to treat acute SCI.

Dissertation (Ph.D.)--University of South Florida, 2006. / Includes vita. Includes bibliographical references (leaves 86-105). Also available online.

Made available in DSpace on 2015-12-06T23:45:03Z (GMT). No. of bitstreams: 0 Previous issue date: 2011 / BV UNIFESP: Teses e dissertações